Physician profile
Robert E Ostendorf
NPI 1003833021
$1,078.90
in general payments reported to CMS, 2019-2025
15 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $104 · 2021: $240 · 2022: $237 · 2023: $72.42 · 2024: $99.74 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $475.77 | 2019-2025 | |
| Genzyme Corporation | $140.73 | 2021-2025 | |
| Glaxosmithkline, LLC. | $95.07 | 2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $55.53 | 2021-2025 | Dupixent |
| Ethicon US, LLC | $54.90 | 2021 | |
| Intersect Ent, INC. | $47.69 | 2019-2020 | |
| Kaleo, INC. | $36.22 | 2022 | |
| Phathom Pharmaceuticals, INC. | $32.58 | 2024 | Voquezna |
| Stryker Corporation | $25.57 | 2019 | |
| Merck Sharp & Dohme LLC | $25.54 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $21.74 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.92 | 2025 | Xhance |
| Aytu Biopharma, INC. | $18.59 | 2020 | |
| Inspire Medical Systems, INC. | $15.42 | 2025 | Inspire |
| Hikma Pharmaceuticals USA | $14.63 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ostendorf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.